HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Johnson, A. J. Articles by Pease, L. R. Search for Related Content PubMed PubMed Citation Articles by Johnson, A. J. Articles by Pease, L. R.

Antigen-Specific CD8⁺ T Cells Mediate a Peptide-Induced Fatal Syndrome¹

Aaron J. Johnson^*,, Yanice Mendez-Fernandez^*, Ann M. Moyer^*, Cari R. Sloma^*, Istvan Pirko, Matthew S. Block^*, Moses Rodriguez^*, and Larry R. Pease^2,*,

Departments of^* Immunology, Neurology, and Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN 55905

Peptide immunotherapy both activates and suppresses the T cell response against known peptide Ags. Although pretreatment with VP2_121–130 peptide inhibits the development of antiviral CTL specific for the immunodominant D^b:VP2_121–130 epitope expressed during acute Theiler’s murine encephalomyelitis virus infection, i.v. injection of this same peptide or MHC tetramers containing the peptide during an ongoing antiviral CTL response results in a peptide-induced fatal syndrome (PIFS) within 48 h. Susceptibility to PIFS is dependent on peptide-specific CD8⁺ T cells, varies among inbred strains of mice, and is not mediated by traditionally defined mechanisms of shock. Analyses using bone marrow chimeras and mutant mice demonstrate that susceptibility to PIFS is determined by the genotype of bone marrow-derived cells and requires the expression of perforin. Animals responding to peptide treatment with PIFS develop classical stress responses in the brain. These findings raise important considerations for the development of peptide therapies for active diseases to modify immune responses involving expanded populations of T cells. In summary, treatment with peptides or MHC-tetramers during a peptide-specific immune response can result in a fatal shock-like syndrome. Susceptibility to the syndrome is genetically determined, is mediated by CD8⁺ T cells, and requires expression of perforin. These findings raise concerns about the use of peptides and MHC tetramers in therapeutic schemes.

This article has been cited by other articles:

				I. Pirko, T. K. Nolan, S. K. Holland, and A. J. Johnson Multiple Sclerosis: Pathogenesis and MR Imaging Features of T1 Hypointensities in Murine Model Radiology, March 1, 2008; 246(3): 790 - 795. [Abstract] [Full Text] [PDF]

				M. T. Getts, B. S. Kim, and S. D. Miller Differential Outcome of Tolerance Induction in Naive versus Activated Theiler's Virus Epitope-Specific CD8+ Cytotoxic T Cells J. Virol., June 15, 2007; 81(12): 6584 - 6593. [Abstract] [Full Text] [PDF]